Dr. Tobias Bonifert, Head of Vector Technology, CEVEC Pharmaceuticals GmbH
Articles
Reduction of Product-related Impurities during Production of recombinant Adeno-Associated Viruses
Dr. Michelle Hussong, Head of Molecular Biology - Technology and Assay Development, CEVEC Pharmaceuticals GmbH;Dr. Tobias Bonifert, Head of Vector Technology, CEVEC Pharmaceuticals GmbH;Prof. Dr. Nico Scheer, Senior Consultant Business Development, CEVEC Pharmaceuticals GmbH, Professor in Molecular Biology at FH Aachen, University of Applied Sciences, Germany
June 9th 2022Latest Updated Articles
Published: September 11th 2024 | Updated: September 18th 2024
CPHI Pharma Award Finalists Announced for 2024
Published: March 27th 2024 | Updated: June 28th 2024
AbbVie Acquires Landos Biopharma and Gets Full FDA Nod for ADC Product
Published: December 9th 2024 | Updated: December 22nd 2024
Recap Key Industry Trends for Viral Clearance and NGS
Published: December 7th 2024 | Updated: December 22nd 2024
Enhancing Quality Through Training
Published: July 20th 2020 | Updated: December 22nd 2024
Contact BioPharm International Editors
Published: July 19th 2020 | Updated: December 22nd 2024
Editorial Information: BioPharm International Submission Guidelines and Editorial Calendars
